Not another weight loss drug. Brenipatide is Eli Lilly's monthly GLP-1/GIP agonist built specifically for addiction, mental health, and conditions where showing up for weekly injections doesn't happen reliably.
🔑 Key Takeaways
- Brenipatide (LY-3537031) is a dual GLP-1/GIP receptor agonist developed by Eli Lilly, designed for once-monthly subcutaneous injection instead of the weekly dosing used by tirzepatide and semaglutide
- It targets the same two receptors as tirzepatide (Mounjaro/Zepbound) but is not being developed as a weight loss competitor. Its primary focus is addiction and psychiatric conditions
- Phase 3 trials are underway for alcohol use disorder and bipolar disorder. Phase 2 trials are running for asthma, smoking cessation, schizophrenia, and opioid use disorder. Phase 1 covers obesity, cardiovascular, liver, and metabolic conditions
- The monthly dosing is not a convenience feature. It's a clinical necessity. Addiction treatment discontinuation exceeds 50% in the first month with oral medications, and psychiatric populations have well-documented adherence challenges with weekly injectables
- Brenipatide has a longer elimination half-life than both tirzepatide and retatrutide, which is what enables the monthly dosing schedule
- No published efficacy data exists yet. The earliest FDA approval would be around 2028, assuming Phase 3 trials for alcohol use disorder succeed
This is the first GLP-1 class molecule that was never designed for obesity. Here's what it is, why Lilly is betting on it, and what the science actually shows so far.
What Is Brenipatide?
A monthly injectable peptide.
Brenipatide (development code LY-3537031) is a synthetic peptide with a molecular weight of approximately 4,892 g/mol. It activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide), the same two targets as tirzepatide. The difference is how it was engineered and what it was engineered for.
Tirzepatide was designed to maximize metabolic effects for weight loss and blood sugar control. Brenipatide was designed to last longer in the body, enabling once-monthly dosing, and it's being pointed at populations where weekly compliance is a real barrier: people with alcohol dependence, opioid addiction, schizophrenia, bipolar disorder, and major depression.
The GLP-1/GIP mechanism is the same. The pharmacokinetic profile, the target population, and the clinical strategy are completely different.
How Brenipatide Works
Same receptors, different purpose.
GLP-1 and GIP are incretin hormones. When you eat, they signal the pancreas to release insulin, slow gastric emptying, and communicate with the brain to reduce appetite. Drugs that activate these receptors mimic that signaling at sustained, therapeutic levels.
But these receptors aren't only in the gut and pancreas. GLP-1 receptors are expressed throughout the brain: the hypothalamus, nucleus accumbens, ventral tegmental area, and amygdala. These are the regions that govern reward processing, craving, impulse control, and mood regulation. That's the biological basis for brenipatide's addiction and psychiatric applications.
The theory, supported by growing evidence from semaglutide and tirzepatide observational data, is that sustained GLP-1/GIP activation in these brain regions modulates dopamine signaling in ways that reduce addictive behaviors and stabilize mood. Retrospective analyses of over 80,000 patients on GLP-1 medications have shown lower rates of alcohol-related medical encounters, reduced depression and anxiety incidence, and lower suicidal ideation.
Brenipatide takes this concept and builds a molecule specifically around it: monthly dosing for populations that won't sustain weekly self-injection, with a receptor profile tuned for neural effects.
Brenipatide Benefits
The potential reach is unusually broad.
Because GLP-1 and GIP receptors exist across metabolic, neural, hepatic, and inflammatory systems, brenipatide's dual agonism produces effects that span multiple organ systems. The benefits below are based on the GLP-1/GIP class mechanism and the specific indications Lilly is pursuing in trials:
Addiction and Craving Reduction
The primary target. GLP-1/GIP activation in the nucleus accumbens and ventral tegmental area modulates the dopamine reward pathway that drives compulsive substance use. Prior GLP-1 agonist data shows reduced alcohol cravings, fewer heavy drinking days, and lower reward-circuit activation in brain imaging studies. The same mechanism applies to nicotine, opioid, and potentially other substance dependencies. Monthly dosing eliminates the adherence gap that undermines daily and weekly addiction treatments.
Mood Stabilization and Depression
GLP-1 receptors in the amygdala and hypothalamus are directly involved in mood regulation and stress response. Retrospective data from semaglutide and tirzepatide users shows lower incidence of depression, anxiety, and suicidal ideation compared to matched controls. Brenipatide's Phase 3 trials for bipolar disorder and major depression are testing whether this observational signal holds up in controlled settings.
Weight Loss (Secondary)
Not the goal, but it will happen. Any GLP-1/GIP agonist suppresses appetite, slows gastric emptying, and shifts metabolic signaling toward fat utilization. Patients on brenipatide for addiction or psychiatric indications will likely experience meaningful weight loss as a side benefit. This matters because psychiatric medications (antipsychotics, mood stabilizers) frequently cause significant weight gain. Brenipatide could offset that.
Liver Protection
Brenipatide shows a skew toward hepatic effects. GLP-1/GIP activation reduces liver fat, improves insulin sensitivity in hepatic tissue, and reduces markers of liver inflammation. For alcohol use disorder patients, who frequently have concurrent alcoholic liver disease or fatty liver, this dual benefit (addiction reduction + liver repair) is particularly relevant.
Anti-Inflammatory Effects (Asthma)
GLP-1 receptor activation has demonstrated anti-inflammatory properties independent of weight loss. The Phase 2 asthma trial is testing whether monthly brenipatide reduces airway inflammation and improves lung function, potentially opening a new therapeutic category for the GLP-1 class.
Metabolic and Cardiovascular
The standard GLP-1/GIP benefits apply: improved blood sugar control, reduced blood pressure, improved lipid profiles, and cardiovascular risk reduction. These are Phase 1 indications for brenipatide, meaning the data is early, but the class-level evidence from tirzepatide and semaglutide is strong.
Potential brenipatide benefits by indication
| Benefit | Evidence level | Trial phase |
|---|---|---|
| Alcohol craving and intake reduction | Strong observational + prior GLP-1 RCT data | Phase 3 |
| Mood stabilization (bipolar) | Observational EHR data | Phase 3 |
| Depression relapse prevention | Observational EHR data | Phase 3 (2026) |
| Smoking cessation support | Mechanistic + early clinical | Phase 2 |
| Opioid use disorder (add-on) | Mechanistic + early clinical | Phase 2 |
| Airway inflammation (asthma) | Class-level anti-inflammatory data | Phase 2 |
| Weight loss | Guaranteed by mechanism, magnitude unknown | Phase 1 |
| Liver fat reduction | Class-level + hepatic skew data | Phase 1 |
Brenipatide Dosage
Limited published data.
Specific dosing protocols for brenipatide have not been publicly disclosed by Eli Lilly. What is known from clinical trial registrations and the molecule's design:
- Frequency: Once monthly subcutaneous injection. This is confirmed across all registered trials.
- Route: Subcutaneous (under the skin), same administration method as tirzepatide and semaglutide.
- Dose range: Phase 2 trials (e.g., asthma, NCT07219173) are evaluating multiple dose levels versus placebo, but the specific mg amounts have not been published.
- Titration: Likely follows the GLP-1 class pattern of starting at a lower dose and escalating over weeks to months to minimize GI side effects. The monthly schedule means titration would occur in monthly increments rather than weekly.
For reference, tirzepatide (same receptor targets, weekly dosing) uses 2.5mg to 15mg per week. Brenipatide's monthly dose would need to deliver sustained receptor activation over 4+ weeks, which likely means a significantly higher absolute dose per injection, offset by the extended half-life that prevents peak-and-trough fluctuations.
What we know about brenipatide dosing
- Once monthly subcutaneous injection (confirmed)
- Multiple dose levels being tested in Phase 2 trials (specific mg not published)
- Extended half-life longer than tirzepatide (~5 days) or retatrutide (~5-6 days) enables the monthly schedule
- Titration likely follows a monthly escalation pattern to manage GI adaptation
- No compounded or commercial version exists, so no community dosing protocols are available
Brenipatide vs Tirzepatide vs Retatrutide
Three different strategies from the same class.
| Feature | Brenipatide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 + GIP | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Dosing frequency | Once monthly | Once weekly | Once weekly |
| Primary indication | Addiction, psychiatric | Weight loss, diabetes | Weight loss, obesity |
| Developer | Eli Lilly | Eli Lilly | Eli Lilly |
| Highest phase | Phase 3 (AUD, bipolar) | Approved (Mounjaro/Zepbound) | Phase 3 (TRIUMPH) |
| Max weight loss (trials) | No data yet | ~21% body weight | ~24% body weight |
| Half-life | Longer than tirzepatide | ~5 days | ~5-6 days |
| Metabolic focus | Liver-skewed profile | Broad metabolic | Fat oxidation emphasis |
All three are Eli Lilly compounds. Tirzepatide is already FDA-approved and dominant in the weight loss space. Retatrutide adds the glucagon receptor for even greater fat loss and is in Phase 3 TRIUMPH trials. Brenipatide is Lilly's bet that the same receptor class can solve problems far beyond body weight.
Clinical Trials: What's Being Studied
Seven indications simultaneously. That's unusual.
No other GLP-1 class molecule has launched this many clinical programs at once. Here's where brenipatide stands:
Phase 3 (Late-stage)
Alcohol use disorder (AUD): The lead indication. Prior evidence includes an exenatide study showing reduced activation of reward circuits in the brain's ventral striatum, a semaglutide randomized controlled trial demonstrating reduced heavy drinking days, and electronic health record data from 80,000+ patients showing fewer alcohol-related medical encounters among GLP-1 users. Brenipatide's Phase 3 AUD trials (RENEW program) are the largest controlled test of whether GLP-1/GIP activation can treat alcoholism.
Bipolar disorder: Phase 3 initiation. The hypothesis is that sustained GLP-1/GIP receptor activation stabilizes mood through metabolic and neuroinflammatory pathways.
Major depressive disorder: Phase 3 planned for 2026. Brenipatide would be added to standard-of-care antidepressants to evaluate whether it delays relapse.
Phase 2 (Mid-stage)
Asthma: Testing whether the anti-inflammatory effects of GLP-1 activation extend to airway inflammation, independent of weight loss. This is a novel application with limited precedent.
Smoking cessation: Evaluating whether brenipatide reduces relapse in adults who have recently quit cigarettes. The reward-modulation mechanism is the same as the AUD hypothesis.
Schizophrenia: Protocol RENEW-Scz-1, studying brenipatide as an add-on to existing antipsychotic medication. GLP-1 agonists have shown preliminary signals in metabolic comorbidities common in schizophrenia patients.
Opioid use disorder: Protocol RENEW-Op-1, studying brenipatide added to buprenorphine maintenance therapy. Targets the same reward-circuit modulation as the alcohol indication.
Phase 1 (Early-stage)
Cardiovascular disorders, liver disorders, metabolic disorders, and obesity. The liver focus is notable: brenipatide shows "a definite skew toward its impact on the liver," suggesting potential applications in alcohol-related liver disease or metabolic-associated fatty liver disease.
Why Monthly Dosing Changes Everything
This isn't about convenience.
In weight loss, weekly injection is manageable. Most people are motivated, tracking progress, and invested in the outcome. The adherence rate reflects that.
Addiction and psychiatric populations are different. Oral naltrexone for alcohol dependence has a discontinuation rate exceeding 50% in the first month. Schizophrenia treatment has historically required long-acting injectable antipsychotics (monthly or quarterly) because daily pill adherence fails at clinically unacceptable rates. Depression treatment discontinuation is a primary driver of relapse.
Brenipatide's monthly formulation is designed for these realities. One injection per month, administered in a clinical setting if needed, eliminates the compliance variable that undermines treatment in these populations. The extended half-life that enables this schedule wasn't a convenience optimization. It was the entire design premise.
Side Effects: What to Expect
Limited data so far.
No large-scale side effect data from brenipatide trials has been published yet. However, the GLP-1/GIP receptor agonist class has a well-characterized safety profile from years of semaglutide and tirzepatide use:
- GI effects: Nausea, vomiting, diarrhea, constipation. These are expected with any GLP-1 agonist. Monthly dosing may produce a different GI side effect pattern than weekly drugs, but this hasn't been characterized yet.
- Appetite suppression: Will occur even though it's not the primary intent. Weight loss is a predictable secondary effect.
- Drug interactions: In psychiatric populations taking antipsychotics, mood stabilizers, or buprenorphine, drug-drug interactions and additive GI effects remain open questions that the trials should address.
- Psychiatric concerns: The FDA investigated GLP-1 agonists for suicidal ideation signals and found no causal link. Brenipatide's psychiatric trials will generate the most detailed data on this question to date.
For a detailed breakdown of what GLP-1/GIP side effects look like in practice, the tirzepatide side effects page covers the same receptor class. The Ozempic side effects page covers the GLP-1-only profile.
Can You Get Brenipatide Now?
No.
Brenipatide is investigational. It is not available through compounding pharmacies, peptide suppliers, or any commercial channel. The only access is through Eli Lilly's clinical trials (clinicaltrials.gov lists active enrollment for several RENEW program studies).
If you're interested in the GLP-1/GIP mechanism for weight loss or metabolic health, compounded tirzepatide targets the same two receptors and is available now. For the triple-agonist version that adds glucagon receptor activation, retatrutide is available through licensed peptide suppliers.
Frequently Asked Questions
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Brenipatide is an investigational compound with no published efficacy data. It is not available for purchase or prescription outside of clinical trials. If you are struggling with alcohol use disorder, opioid dependence, or mental health conditions, consult a licensed healthcare provider for evidence-based treatment options.